Abstract
AIM: The aim of the study was to examine if statin exposure during neoadjuvant chemoradiotherapy improves oncological outcomes in patients with rectal cancer. PATIENTS AND METHODS: The study cohort consisted of patients who were undergoing neoadjuvant chemoradiotherapy and resection for rectal cancer. The statin users were matched 1:1 with non-users using propensity score-based matching. The primary outcome of the study was disease-free survival; secondary outcomes were recurrence-free survival and all-cause mortality. RESULTS: A total of 704 patients were included in the study. Disease-free survival was not different between the two groups [hazard ratio (HR)=0.98, 95% confidence intervaI (CI)=0.77-1.25, p=0.88]. Both recurrence-free survival (HR=1.02, 95% CI=0.74-1.39, p=0.92) and all-cause mortality (HR=0.92, 95% CI=0.68-1.23, p=0.56) were similar for the two groups. CONCLUSION: The study does not support that statin use is associated with response to neoadjuvant chemoradiotherapy in terms of disease-free survival, recurrence-free survival or all-cause mortality.
| Original language | English |
|---|---|
| Journal | Anticancer Research |
| Volume | 39 |
| Issue number | 4 |
| Pages (from-to) | 2177-2182 |
| ISSN | 0250-7005 |
| DOIs | |
| Publication status | Published - Apr 2019 |
Fingerprint
Keywords
- chemoradiotherapy
- Rectal cancer
- statins
- Humans
- Middle Aged
- Male
- Treatment Outcome
- Chemoradiotherapy
- Aged, 80 and over
- Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
- Female
- Neoadjuvant Therapy
- Aged
- Rectal Neoplasms/mortality
Cite this
}
Association of Statin Use and Oncological Outcomes After Neoadjuvant Radiotherapy in Patients With Rectal Cancer. / Fransgaard, Tina; Hallas, Jesper; Thygesen, Lau Caspar; Gögenur, Ismail.
In: Anticancer Research, Vol. 39, No. 4, 04.2019, p. 2177-2182.Research output: Contribution to journal › Journal article › Research › peer-review
TY - JOUR
T1 - Association of Statin Use and Oncological Outcomes After Neoadjuvant Radiotherapy in Patients With Rectal Cancer
AU - Fransgaard, Tina
AU - Hallas, Jesper
AU - Thygesen, Lau Caspar
AU - Gögenur, Ismail
PY - 2019/4
Y1 - 2019/4
N2 - AIM: The aim of the study was to examine if statin exposure during neoadjuvant chemoradiotherapy improves oncological outcomes in patients with rectal cancer. PATIENTS AND METHODS: The study cohort consisted of patients who were undergoing neoadjuvant chemoradiotherapy and resection for rectal cancer. The statin users were matched 1:1 with non-users using propensity score-based matching. The primary outcome of the study was disease-free survival; secondary outcomes were recurrence-free survival and all-cause mortality. RESULTS: A total of 704 patients were included in the study. Disease-free survival was not different between the two groups [hazard ratio (HR)=0.98, 95% confidence intervaI (CI)=0.77-1.25, p=0.88]. Both recurrence-free survival (HR=1.02, 95% CI=0.74-1.39, p=0.92) and all-cause mortality (HR=0.92, 95% CI=0.68-1.23, p=0.56) were similar for the two groups. CONCLUSION: The study does not support that statin use is associated with response to neoadjuvant chemoradiotherapy in terms of disease-free survival, recurrence-free survival or all-cause mortality.
AB - AIM: The aim of the study was to examine if statin exposure during neoadjuvant chemoradiotherapy improves oncological outcomes in patients with rectal cancer. PATIENTS AND METHODS: The study cohort consisted of patients who were undergoing neoadjuvant chemoradiotherapy and resection for rectal cancer. The statin users were matched 1:1 with non-users using propensity score-based matching. The primary outcome of the study was disease-free survival; secondary outcomes were recurrence-free survival and all-cause mortality. RESULTS: A total of 704 patients were included in the study. Disease-free survival was not different between the two groups [hazard ratio (HR)=0.98, 95% confidence intervaI (CI)=0.77-1.25, p=0.88]. Both recurrence-free survival (HR=1.02, 95% CI=0.74-1.39, p=0.92) and all-cause mortality (HR=0.92, 95% CI=0.68-1.23, p=0.56) were similar for the two groups. CONCLUSION: The study does not support that statin use is associated with response to neoadjuvant chemoradiotherapy in terms of disease-free survival, recurrence-free survival or all-cause mortality.
KW - chemoradiotherapy
KW - Rectal cancer
KW - statins
KW - Humans
KW - Middle Aged
KW - Male
KW - Treatment Outcome
KW - Chemoradiotherapy
KW - Aged, 80 and over
KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
KW - Female
KW - Neoadjuvant Therapy
KW - Aged
KW - Rectal Neoplasms/mortality
U2 - 10.21873/anticanres.13332
DO - 10.21873/anticanres.13332
M3 - Journal article
VL - 39
SP - 2177
EP - 2182
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 4
ER -